In this paper, it is presented persistent hypomagnesemia and secondary tetany in two patients with ovarian cancer who have received cisplatin chemotherapy and it is also discusse clinical presentation, causes, prophylaxis and treatment choises of cisplatin induced hypomagnesemia by the literature.
📌 3 Key Takeaways
🎯
Objective & Hypothesis:In this paper, it is presented persistent hypomagnesemia and secondary tetany in two patients with ovarian cancer who have received cisplatin chemotherapy and it is also discusse clinical presentation, causes, prophylaxis and treatment choises of cisplatin induced hypomagnesemia by the literature.
📊
Key Findings & Data:In this paper, it is presented persistent hypomagnesemia and secondary tetany in two patients with ovarian cancer who have received cisplatin chemotherapy and it is also discusse clinical presentation, causes, prophylaxis and treatment choises of cisplatin induced hypomagnesemia by the literature.
💡
Conclusion & Impact:In this paper, it is presented persistent hypomagnesemia and secondary tetany in two patients with ovarian cancer who have received cisplatin chemotherapy and it is also discusse clinical presentation, causes, prophylaxis and treatment choises of cisplatin induced hypomagnesemia by the literature.
In this paper, it is presented persistent hypomagnesemia and secondary tetany in two patients with ovarian cancer who have received cisplatin chemotherapy and it is also discusse clinical presentation, causes, prophylaxis and treatment choises of cisplatin induced hypomagnesemia by the literature.
Özet
Bu makalede, over kanseri sonrası sisplatin içeren kemoterapi protokolü uygulanan iki hastada gelişen persistan hipomagnezemi ve buna sekonder tetani sunuldu. Ayrıca, sisplatine bağlı gelişen hipomagnezeminin klinik prezantasyonu, nedenleri, profılaksi ve tedavi seçenekleri, ilgili literatürün ışığında tartışıldı.
Mune T, Yasuda K, Ishii M, Matsunaga T, Miura K. Tetany due to hypomagnesemia induced by cisplatin and doxorubicin treatment for synovial sarcoma. Intern Med 1993; 32(5): 434-7 2. Lajer H, Daugaard G. Cisplatin and hypomagnesemia. Cancer Treat Rev 1999; 25(1): 47-58 3. Markmann M, Rothman R, Reichman B, Hakes T, Lewis JL Jr, Rubin S, Jones W, Almadrones L, Hoskins W. Persistent hypomagnesemia following cisplatin chemotherapy in patients with ovarian cancer. J Cancer Res Clin Oncol 1991; 117(2):89-90 4. Martin M, Diaz-Rubio E, Casado A, Lopez Vega JM, Sastre J, Almenarez j. Intravenous and oral magnesium supplementations in the prophylaxis of cisplatin-induced hypomagnesemia. Results of a controlled trial. Am J Clin Oncol 1992; 15(4): 348-51 5. McDermott KC, Almadrones LA, Bajonuras DR. The diagnosis and management of hypomagnesemia: a unique treatment approach and case report. Oncol Nurs Forum 1991; 18(7): 1145-52 6. Bachmeyer C, Decroix Y, Medioni J, Dhote R, Benfiguig K et al. Hypomagnesemic and hypocalcemic coma, convulsion and ocular motility disorders after chemotherapy with platinum compounds. Rev Med Interne 1996; 17(6): 467-9 7. Al-Tweigeri T, Magliocco AM, DeCoteau JF. Cortical blindness as a manifestation of hypomagnesemia secondary to cisplatin therapy: case report and review of literature.Gynecol Oncol 1999; 72(1): 120-122.